BTZ is a US Food and Drug Administration- approved inhibitor for the treatment of multiple myeloma and mantle cell lymphoma [33] and is currently under investigation for combination with NK cells in multiple malignancies (NCT00720785). The gene discussed is CASC3; the disease is plasma cell myeloma.